Dentsply Sirona (XRAY) Q3 2026 earnings review
Dentsply Sirona cuts its profit outlook, but catheter sales grow
Dentsply Sirona, which makes dental products, sold less to dentists while its catheter business kept expanding. Sales fell 8% from a year ago. Profit per share excluding one-offs still contained a one-time accounting gain. Without it, profit would have dropped by about two-thirds, by our math. By our math, the company's sales plan also leaves the fourth quarter about 8% down.
| Sales without currency moves, the closed Byte business and dealer stock cuts | −3.8% −7.6% as reported |
|---|---|
| Profit per share, excluding one-offs | $0.29 $0.42 a year ago; about $0.14 without the accounting gain |
| Wellspect catheter sales | $92M +10.1% from a year ago |
| Full-year profit-per-share outlook | Cut to $1.20–1.30 was $1.40–1.50 |
⚖️ Verdict: 🔴 Bearish
The story got worse, because chief executive Dan Scavilla cut the profit plan for the third year in a row. The good news: Wellspect, its catheter unit, set a sales record. Dental sales still fell even though the US sales team now has far fewer empty posts.
The question now is why sales of dental supplies in Europe keep falling. Scavilla blames dealers running down their stock; the other reading is a lasting loss to low-cost rivals. Fourth-quarter sales of dental supplies in Europe will tell.
🐂 Bull Case
Catheter Unit Wellspect Sets a Sales Record
Wellspect, Dentsply Sirona's non-dental unit, makes catheters and other products for people with bladder and bowel problems. Chief executive Dan Scavilla said it set a quarterly sales record, with sales up 10.1% as reported.
Wellspect finished its US Surity range, which adds external catheters and a home urine-collection system "for people managing incontinence at home". In October, the range qualified for traditional Medicare coverage.
- Americas sales: up 77.3%
- Share of group sales: 11.0%, from 9.2% a year ago
- Operating profit: $25 million, from $28 million
Wellspect was the only unit that grew, but at a tenth of sales it cannot offset the dental decline. Its profit slipped because it hired staff and advertised to push Surity.
What to watch: Wellspect's fourth-quarter growth, its first full quarter with Medicare coverage. Double-digit growth again would show the launches can lift profit as well as sales.
Fewer Empty Sales Posts and Early US Gains
Dentsply Sirona's turnaround plan, which it calls the Return-to-Growth Action Plan, starts with a stable US sales force. Scavilla said quota-carrying field vacancies "are now in the mid-single digits, down from more than 20% in prior years".
Two product lines showed early gains. US sales of MIS, the group's lower-priced implant brand, grew by double digits, and US sales of root-canal products rose 4%.
These are the first readings on hires and dealer deals made this year, so they are early. Americas sales still fell 9.6% at constant exchange rates, and Scavilla called US growth by the fourth quarter "a stretch".
What to watch: US sales in the fourth quarter, which Scavilla wants above last year's level. A rise would show the rebuilt sales team adds revenue, not only activity.
Positives this quarter didn't test
Three smaller positives from earlier quarters got little new evidence in these results, so each still waits for a clear number before it can support the turnaround case.
- Equipment in Asia Pacific: scanners and milling machines sold well in Japan, but the region's equipment sales still fell 2.5% at constant exchange rates; a rise would confirm the program.
- Bone-repair products: Dentsply Sirona won approval to bring OSSIX Plus, a collagen membrane, back to the US and Canada; first sales would show demand.
- Aligners in Europe: SureSmile, the group's clear aligner brand, grew 8% in the region, finance chief John Fortson said; steady growth would show the brand holds up outside the US.
🐻 Bear Case
The Profit Outlook Falls for a Third Year
Dentsply Sirona cut its full-year plan for profit per share, excluding one-offs, to $1.20–1.30 from $1.40–1.50. The dental group also lowered its profit plans in 2024 and 2025. Most of this cut came from Europe, the Middle East and Africa, a region it calls EMEA.
Finance chief John Fortson said "EMEA underperformance and the Middle East conflict accounted for roughly three-fourths of the reduction". In EMEA, sales fell 5.6% at constant exchange rates. The dental supplies unit, which sells root-canal files and fillings, lost 6.5% there. Scavilla said Western European dealers now hold less stock, and Fortson cited "pricing pressure from lower-cost entrants" in equipment.
This matters because the gaps keep widening. Excluding currency moves, the closed Byte business and dealer stock cuts, sales fell 3.8%, Fortson said, below the range set in the first quarter. The new profit range also keeps this quarter's $0.15 accounting gain. Without it, the middle of the range is about $1.10 by our math, 31% below last year.
What to watch: dental supplies sales in EMEA in the fourth quarter. A further drop after dealers have already trimmed stock would point to customers moving to cheaper rivals.
Without an Accounting Gain, Margins Shrank
Dentsply Sirona said its gross margin excluding one-offs rose 1.9 percentage points. That figure keeps a $39 million gain from a new way of counting profit on stock its units sell to each other. Fortson said the gain "reflects a multi-year period rather than third quarter operating performance".
Without the gain, that margin fell to 49.9% from 52.6%, by our math. Selling and overhead costs took 4.0 percentage points more of revenue, because the group paid for clinical training and wrote off unpaid bills.
- Equipment unit operating profit: a $3 million loss, against a $10 million profit
- Implant and aligner unit operating profit: a $1 million loss, against $22 million
- Aligner sales: down 26%, partly because the closed Byte business no longer sells
So the damage sits in the equipment unit and the implant and aligner unit. Scavilla said other one-offs cancel the gain: "There are offsetting one-time events bringing it down to negligible." He named none, and those two units' profit still fell by $36 million.
What to watch: gross margin excluding one-offs in the fourth quarter, the first without the gain. A figure near 50% would show that the lost 3 points are the real level.
Debt Rises and Lenders Loosen the Limits
Fortson said the company will "prioritize debt reduction as a core tenet of our capital allocation strategy". Yet net debt, its borrowing minus cash, rose $20 million from June to about $2.0 billion, by our math.
Fortson put net debt at 3.4 times EBITDA, a yearly measure of operating profit before interest, tax and write-downs. In October, lenders agreed to raise the ceilings on that ratio, giving Dentsply Sirona "additional flexibility to maintain compliance with its debt covenants". The new terms also restrict some payouts for a time and raise interest at higher debt levels.
- Free cash flow: zero, against $40 million a year ago
- Share buybacks: $13 million in the quarter
- Net debt to EBITDA: 3.4 times, against 3.2 times in June
This cuts against the stated priority, because the group bought back shares in a quarter with no free cash. It scrapped its dividend this year to fund debt repayment and buybacks. Even so, net debt sits only $27 million below a year ago.
What to watch: the debt ratio at year-end, which depends on fourth-quarter cash flow. A ratio still above 3.4 times would leave Dentsply Sirona relying on the looser covenant terms.
Risks this quarter didn't answer
Three standing risks from earlier quarters got new court or staffing news this quarter, but none got a number or a ruling that settles it.
- Byte lawsuit: Dentsply Sirona agreed terms to settle the 2024 shareholder suit over its closed Byte aligner business for $75 million, which insurers will pay; court approval would close it.
- Tax disputes: a German prosecutor's inquiry into 2016–2017 company loans and an IRS claim over a $451 million payout show no change; any ruling would move the case.
- Management turnover: Fortson completed his first full quarter as finance chief after repeated changes in the post; a full year without another change would ease the risk.
👓 Other Themes
A Cheaper Scanner That Runs on Existing PCs
At its DS World events, Dentsply Sirona introduced Primescan Connect, a dental scanner that works with DS Core, its cloud-based software platform. Scavilla called it "our most affordable scanner option". Practices can run it on a compatible PC they already own, without separate scanning licences. The group has given no sales figures for it yet.
Dentists Remain Careful About Buying Equipment
Dentsply Sirona's filing says weak economic conditions have hurt "the ability and willingness of clinicians to obtain financing to purchase equipment", especially in the US. Scavilla said customers "weigh investments in equipment carefully". Tariff refunds also faded: the company received $3 million this quarter, against $44 million in the second quarter.
💲 Other KPIs
Capital spending is climbing for the year, even though it slipped to 3.8% of sales this quarter. Over nine months it reached $128 million, up from $90 million. The filing raised the full-year estimate to $165–185 million, for factory upgrades, DS Core and new business software. By our math, that leaves $37–57 million for the fourth quarter.
Inventory kept building while sales shrank. It reached $707 million at the end of September, 10% more than in December. Stock now covers 152 days of sales, against 131 days in December, the filing said. Dentsply Sirona set a goal to cut inventory by a fifth, so it is moving away from that target and tying up cash.
Deferred revenue, cash customers paid in advance for orthodontic treatments not yet delivered, kept shrinking. It stood at $99 million, 2.9% below June. The group recognised only $9 million from its opening balance this quarter, against $30 million a year earlier, a sign that aligner volumes keep falling.
🔮 Guidance
Cut. The plan now sits at the bottom of the old range, about 5% below last year. By our math, it leaves about $886 million for the fourth quarter, 7.8% below a year ago. That matches this quarter's decline, even though Fortson said the fourth quarter is normally a good quarter for equipment.
Cut. The middle of the range fell $0.20 after three quarters unchanged. The plan leaves out the $0.17 tariff refund but keeps the $0.15 accounting gain. By our math, it leaves $0.29–0.39 for the fourth quarter, against $0.27 a year ago. Fortson called that "fairly doable", counting on equipment sales and a richer product mix.
❓ Key Questions
Which one-time costs offset the $39 million gain?
Scavilla said other one-off items cut the gain's net effect to almost nothing. Without a list, readers cannot judge whether this quarter's profit, and the full-year plan, reflect the running business.
Will the restructuring save $100 million or $120 million?
The filing now puts the 2026 plan's yearly savings at about $100 million, while earlier filings and the slides cite $120 million. The profit plan depends on which figure is right.
How much of Europe's decline comes from dealers cutting stock?
The filing says Dentsply Sirona cannot quantify how much lower dealer stock cut European sales of dental supplies. That number decides whether the region recovers on its own or has lost customers.
Did dental supplies prices rise or fall this quarter?
The filing blames "unfavorable pricing" for lower dental supplies sales, yet credits "favorable pricing" for the unit's 22% profit gain. Readers need to know which price moves happened where.
Do the new loan terms limit share buybacks?
The October amendments restrict certain payments to shareholders for a time. Dentsply Sirona should say whether that covers buybacks, which it restarted this year after scrapping the dividend.